Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
暂无分享,去创建一个
[1] R. Beart,et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. , 2015, Journal of the National Cancer Institute.
[2] C. Allegra,et al. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials , 2015, Current Colorectal Cancer Reports.
[3] T. Hothorn,et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[4] Geert Molenberghs,et al. On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints , 2015, Biometrics.
[5] P. Lambin,et al. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] B. Erickson,et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. , 2015, International journal of radiation oncology, biology, physics.
[7] M. Sormani,et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Zhi-rui Zhou,et al. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. , 2014, Surgical oncology.
[9] C. Orlandini,et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] J. Lindebjerg,et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. , 2014, International journal of radiation oncology, biology, physics.
[11] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[12] J. Park,et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. , 2014, The Lancet. Oncology.
[13] N. Petrelli,et al. Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early-phase trials. , 2014 .
[14] E. Sağlam,et al. Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. , 2013, Journal of gastrointestinal oncology.
[15] C. Willett,et al. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. , 2013, International journal of radiation oncology, biology, physics.
[16] Xi Lin,et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. , 2013, European journal of cancer.
[17] D. Goldstein,et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Conroy,et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Collette,et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? , 2012, European journal of cancer.
[20] H. Heneghan,et al. Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer , 2012, The British journal of surgery.
[21] P. Kienle,et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.
[22] W. Hohenberger,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Kulig,et al. Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer—treatment results at 5-year follow-up , 2011, Langenbeck's Archives of Surgery.
[24] Jong Hoon Kim,et al. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer , 2011, Cancer.
[25] M Buyse,et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. , 2011, European journal of cancer.
[26] Karin Haustermans,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.
[27] Brian Bot,et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] N. Petrelli,et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Monson,et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.
[30] R. Labianca,et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Lars Påhlman,et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] H. Putter,et al. The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma , 2007, Annals of surgery.
[33] Daniel J Sargent,et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Siu,et al. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Sydes,et al. Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.
[36] Bernard Leduc,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] K. Bujko,et al. Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.
[38] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[39] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[40] O. Chapet,et al. Long‐term results of the Lyons R90‐01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter‐saving surgery in rectal cancer , 2003, The British journal of surgery.
[41] D. Sengupta. Linear models , 2003 .
[42] Paula R Williamson,et al. Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.
[43] Rieken,et al. [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer]. , 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[44] R J Carroll,et al. On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.
[45] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[46] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[47] D. Altman,et al. Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects. , 1995, BMJ.